Biomedical applications of bisphosphonates

Journal of Controlled Release

Volumn 167, Issue 2, 2013, Pages 175-188

  Giger, Elisabeth V ^a   Castagner, Bastien ^a   Leroux, Jean Christophe ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Bisphosphonate; Drug conjugates; Implant; Nanomedicine; Osteoporosis; Targeting

Indexed keywords

BIOMEDICAL APPLICATIONS; BISPHOSPHONATES; DRUG-CONJUGATES; ORAL BIOAVAILABILITIES; OSTEOPOROSIS; PHARMACOLOGICAL ACTIVITY; POSTMENOPAUSAL WOMEN; TARGETING;

BIOCHEMISTRY; BONE; CORROSION INHIBITORS; HYDROXYAPATITE; IMPLANTS (SURGICAL); MEDICAL APPLICATIONS; MEDICAL NANOTECHNOLOGY; TISSUE;

DISEASES;

ALENDRONIC ACID; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CEFALOTIN; CIPROFLOXACIN; CLODRONIC ACID; CORTICOSTEROID; DOXORUBICIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTRADIOL; ETIDRONIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; HYDROXYAPATITE; IBANDRONIC ACID; MOXIFLOXACIN; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; POLYGLACTIN; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; RHENIUM 186; RISEDRONIC ACID; SIMVASTATIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TILUDRONIC ACID; UNINDEXED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ACUTE KIDNEY TUBULE NECROSIS; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; BACTERIAL ARTHRITIS; BACTERIUM ADHERENCE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PAIN; CHRONIC WOUND; CLINICAL TRIAL (TOPIC); CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG INDUSTRY; DRUG STRUCTURE; ENDOMETRIOSIS; EYE INFLAMMATION; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HIP FRACTURE; HUMAN; HYPERCALCEMIA; IN-STENT RESTENOSIS; JAW OSTEONECROSIS; KIDNEY CALCIFICATION; KIDNEY FAILURE; LIPOSOMAL DELIVERY; MATERIAL COATING; MESENCHYMAL STEM CELL; NAUSEA; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOGENESIS IMPERFECTA; OSTEOMYELITIS; OSTEOPOROSIS; PAGET BONE DISEASE; PERTHES DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVIEW; SCANNING ELECTRON MICROSCOPY; SIDE EFFECT; SINGLE DRUG DOSE; SKIN IRRITATION; SPINE FRACTURE; STRESS FRACTURE; UTERUS WEIGHT;

ANIMALS; DIPHOSPHONATES; DRUG DELIVERY SYSTEMS; HUMANS;

EID: 84874398318     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.01.032     Document Type: Review

References (191)

1. H. Fleisch Development of bisphosphonates Breast Cancer Res. 4 2002 30 34
2. G.A. Petroianu Pharmacist Theodor Salzer (1833-1900) and the discovery of bisphosphonates Pharmazie 66 2011 804 807
3. H. Fleisch, and S. Bisaz Isolation from urine of pyrophosphate, a calcification inhibitor Am. J. Physiol. 203 1962 671 675
4. H. Fleisch, R.G.G. Russell, and F. Straumann Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis Nature 212 1966 901 903
5. M.B. Hoagland, M.L. Stephenson, J.F. Scott, L.I. Hecht, and P.C. Zamecnik A soluble ribonucleic acid intermediate in protein synthesis J. Biol. Chem. 231 1958 241 257
6. H. Fleisch, R.G.G. Russell, S. Bisaz, P.A. Casey, and R.C. Mühlbauer The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo Calcif. Tissue Int. 2 1968 10-10A
7. H. Fleisch, R.G.G. Russell, and D.F. Marion Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo Science 165 1969 1262 1264
8. M.D. Francis, R. Graham, G. Russell, and H. Fleisch Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo Science 165 1969 1264 1266
9. M.D. Francis, and D.J. Valent Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases J. Musculoskelet. Neuronal Interact. 7 2007 2 8
10. C. Bassett, A. Donath, F. Macagno, R. Preisig, H. Fleisch, and M.D. Francis Diphosphonates in the treatment of myositis ossificans Lancet 18 1969 845
11. G.H. Nancollas, R. Tang, R.J. Phipps, Z. Henneman, S. Gulde, W. Wu, A. Mangood, R.G.G. Russell, and F.H. Ebetino Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone 38 2006 617 627
12. R. Russell, N. Watts, F. Ebetino, and M. Rogers Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos. Int. 19 2008 733 759
13. G.A. Rodan, and T.J. Martin Therapeutic approaches to bone diseases Science 289 2000 1508 1514
14. G. Bansal, J.E.I. Wright, C. Kucharski, and H. Uludag A dendritic tetra(bisphosphonic acid) for improved targeting of proteins to bone Angew. Chem. Int. Ed. 44 2005 3710 3714
15. K. Ogawa, T. Mukai, Y. Arano, M. Ono, H. Hanaoka, S. Ishino, K. Hashimoto, H. Nishimura, and H. Saji Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals Bioconjug. Chem. 16 2005 751 757
16. M. Morioka, A. Kamizono, H. Takikawa, A. Mori, H. Ueno, S.-I. Kadowaki, Y. Nakao, K. Kato, and K. Umezawa Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens Bioorg. Med. Chem. 18 2010 1143 1148
17. K.S.E. Tanaka, T.J. Houghton, T. Kang, E. Dietrich, D. Delorme, S.S. Ferreira, L. Caron, F. Viens, F.F. Arhin, I. Sarmiento, D. Lehoux, I. Fadhil, K. Laquerre, J. Liu, V. Ostiguy, H. Poirier, G. Moeck, T.R. Parr Jr., and A. Rafai Far Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis Bioorg. Med. Chem. 16 2008 9217 9229
18. H.D. Danenberg, I. Fishbein, H. Epstein, J. Waltenberger, E. Moerman, J. Mönkkönen, J. Gao, I. Gathi, R. Reichi, and G. Golomb Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery J. Cardiovasc. Pharmacol. 42 2003 671 679
19. H.D. Danenberg, I. Fishbein, J. Gao, J. Mönkkönen, R. Reich, I. Gati, E. Moerman, and G. Golomb Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits Circ. Res. 106 2002 599 605
20. S.H. Greiner, B. Wildemann, D.A. Back, M. Alidoust, P. Schwabe, N.P. Haas, and G. Schmidmaier Local application of zoledronic acid incorporated in a poly(d, l-lactide)-coated implant accelerates fracture healing in rats Acta Orthop. 79 2008 717 725
21. V.A. Stadelmann, A. Terrier, O. Gauthier, J.M. Bouler, and D.P. Pioletti Prediction of bone density around orthopedic implants delivering bisphosphonate J. Biomech. 42 2009 1206 1211
22. D. Portet, B. Denizot, E. Rump, J.-J. Lejeune, and P. Jallet Nonpolymeric coatings of iron oxide colloids for biological use as magnetic resonance imaging contrast agents J. Colloid Interface Sci. 238 2001 37 42
23. E.V. Giger, B. Castagner, J. Räikkönen, J. Mönkkönen, and J.-C. Leroux siRNA transfection with calcium phosphate nanoparticles stabilized with PEGylated chelators Adv. Healthcare Mater. 2 2013 134 144
24. R. Torres Martin de Rosales, R. Tavaré, A. Glaria, G. Varma, A. Protti, and P.J. Blower 99mTc-bisphosphonate-iron oxide nanoparticle conjugates for dual-modality biomedical imaging Bioconjug. Chem. 22 2011 455 465
25. C. Chapon, F. Franconi, F. Lacoeuille, F. Hindré, P. Saulnier, J.-P. Benoit, J.-J. Le Jeune, and L. Lemaire Imaging E-selectin expression following traumatic brain injury in the rat using a targeted USPIO contrast agent Magn. Reson. Mater. Phys. Biol. Med. 22 2009 167 174
26. M. Sato, W. Grasser, N. Endo, R. Akins, H. Simmons, D.D. Thompson, E. Golub, and G.A. Rodan Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure J. Clin. Invest. 88 1991 2095 2105
27. K. Thompson, M.J. Rogers, F.P. Coxon, and J.C. Crockett Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis Mol. Pharmacol. 69 2006 1624 1632
28. R. Baron, L. Neff, D. Louvard, and P.J. Courtoy Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border J. Cell Biol. 101 1985 2210 2222
29. H. Blair, S. Teitelbaum, R. Ghiselli, and S. Gluck Osteoclastic bone resorption by a polarized vacuolar proton pump Science 245 1989 855 857
30. J.C. Frith, J. Mönkkönen, G.M. Blackburn, R.G.G. Russell, and M.J. Rogers Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro J. Bone Miner. Res. 12 1997 1358 1367
31. P.P. Lehenkari, M. Kellinsalmi, J.P. Näpänkangas, K.V. Ylitalo, J. Mönkkönen, M.J. Rogers, A. Azhayev, H.K. Väänänen, and I.E. Hassinen Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite Mol. Pharmacol. 61 2002 1255 1262
32. E. van Beek, E. Pieterman, L. Cohen, C. Löwik, and S. Papapoulos Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates Biochem. Biophys. Res. Commun. 264 1999 108 111
33. S.P. Luckman, D.E. Hughes, F.P. Coxon, R.G.G. Russell, and M.J. Rogers Nitrogen-containing biphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras J. Bone Miner. Res. 13 1998 581 589
34. J.E. Dunford, K. Thompson, F.P. Coxon, S.P. Luckman, F.M. Hahn, C.D. Poulter, F.H. Ebetino, and M.J. Rogers Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates J. Pharmacol. Exp. Ther. 296 2001 235 242
35. F.P. Coxon, M.H. Helfrich, R. Van't Hof, S. Sebti, S.H. Ralston, A. Hamilton, and M.J. Rogers Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298 J. Bone Miner. Res. 15 2000 1467 1476
36. F.P. Coxon, K. Thompson, and M.J. Rogers Recent advances in understanding the mechanism of action of bisphosphonates Curr. Opin. Pharmacol. 6 2006 307 312
37. J.E. Dunford, M.J. Rogers, F.H. Ebetino, R.J. Phipps, and F.P. Coxon Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases J. Bone Miner. Res. 21 2006 684 694
38. H. Mönkkönen, S. Auriola, P. Lehenkari, M. Kellinsalmi, I.E. Hassinen, J. Vepsäläinen, and J. Mönkkönen A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates Br. J. Pharmacol. 147 2006 437 445
39. F. von Knoch, C. Jaquiery, M. Kowalsky, S. Schaeren, C. Alabre, I. Martin, H.E. Rubash, and A.S. Shanbhag Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells Biomaterials 26 2005 6941 6949
40. T. Bellido, and L.I. Plotkin Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability Bone 49 2011 50 55
41. V. Stresing, F. Daubiné, I. Benzaid, H. Mönkkönen, and P. Clézardin Bisphosphonates in cancer therapy Cancer Lett. 257 2007 16 35
42. S.G. Senaratne, J.L. Mansi, and K.W. Colston The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells Br. J. Cancer 86 2002 1479 1486
43. V. Stresing, P.G. Fournier, A. Bellahcène, I. Benzaïd, H. Mönkkönen, M. Colombel, F.H. Ebetino, V. Castronovo, and P. Clézardin Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase Bone 48 2011 259 266
44. J. Wood, K. Bonjean, S. Ruetz, A. Bellahcène, L. Devy, J.M. Foidart, V. Castronovo, and J.R. Green Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid J. Pharmacol. Exp. Ther. 302 2002 1055 1061
45. A. Ezra, and G. Golomb Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption Adv. Drug Deliv. Rev. 42 2000 175 195
46. J.H. Lin, I.W. Chen, and F.A. Deluna On the absorption of alendronate in rats J. Pharm. Sci. 83 1994 1741 1746
47. P.D. Delmas Treatment of postmenopausal osteoporosis Lancet 359 2002 2018 2026
48. H. Katsumi, M. Nakatani, J.-I. Sano, M. Abe, K. Kusamori, M. Kurihara, R. Shiota, M. Takashima, T. Fujita, T. Sakane, T. Hibi, and A. Yamamoto Absorption and safety of alendronate, a nitrogen-containing bisphosphonate, after intrapulmonary administration in rats Int. J. Pharm. 400 2010 124 130
49. K. Kusamori, H. Katsumi, M. Abe, A. Ueda, R. Sakai, R. Hayashi, Y. Hirai, Y.-S. Quan, F. Kamiyama, T. Sakane, and A. Yamamoto Development of a novel transdermal patch of alendronate, a nitrogen-containing bisphosphonate, for the treatment of osteoporosis J. Bone Miner. Res. 25 2010 2582 2591
50. S.C. Sutton, K. Engle, and J.A. Fix Intranasal delivery of the bisphosphonate alendronate in the rat and dog Pharm. Res. 10 1993 924 926
51. H. Katsumi, M. Takashima, J.-I. Sano, K. Nishiyama, N. Kitamura, T. Sakane, T. Hibi, and A. Yamamoto Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: evaluation of absorption, safety, and effects after intrapulmonary administration in rats J. Pharm. Sci. 100 2011 3783 3792
52. C. Roemer-Bécuwe, A. Vigano, F. Romano, C. Neumann, J. Hanson, H.K. Quan, and P. Walker Safety of subcutaneous clodronate and efficacy in hypercalcemia of malignancy: a novel route of administration J. Pain Symptom Manage. 26 2003 843 848
53. S. Cremers, and S. Papapoulos Pharmacology of bisphosphonates Bone 49 2011 42 49
54. N.B. Watts, and D.L. Diab Long-term use of bisphosphonates in osteoporosis J. Clin. Endocrinol. Metab. 95 2010 1555 1565
55. I. Fogelman, R.G. Bessent, J.G. Turner, D.L. Citrin, I.T. Boyle, and W.R. Greig The use of whole-body retention of Tc-99 m diphosphonate in the diagnosis of metabolic bone disease Br. Med. J. 19 1978 270 275
56. R. Smith, R.G.G. Russell, and M. Bishop Diphosphonates and Paget's disease of bone Lancet 297 1971 945 947
57. H.I. Harinck, S.E. Papapoulos, H.J. Blanksma, A.J. Moolenaar, P. Vermeij, and O.L. Bijvoet Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD) Br. Med. J. 295 1987 1301 1305
58. I.R. Reid, and D.J. Hosking Bisphosphonates in Paget's disease Bone 49 2011 89 94
59. A. Abelson A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg Curr. Med. Res. Opin. 24 2008 695 705
60. H.K. Genant, C. Cooper, G. Poor, I. Reid, G. Ehrlich, J. Kanis, B.E.C. Nordin, E. Barrett-Connor, D. Black, J.P. Bonjour, B. Dawson-Hughes, P.D. Delmas, J. Dequeker, S.R. Eis, C. Gennari, O. Johnell, C.C. Johnston Jr., E.M.C. Lau, U.A. Liberman, R. Lindsay, T.J. Martin, B. Masri, C.A. Mautalen, P.J. Meunier, P.D. Miller, A. Mithal, H. Morii, S. Papapoulos, A. Woolf, W. Yu, and N. Khaltaev Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis Osteoporos. Int. 10 1999 259 264
61. C. Anderson, R. Cape, R. Crilly, A. Hodsman, and B. Wolfe Preliminary observations of a form of coherence therapy for osteoporosis Calcif. Tissue Int. 36 1984 341 343
62. R.P. Heaney, and P.D. Saville Etidronate disodium in postmenopausal osteoporosis Clin. Pharmacol. Ther. 20 1976 593 604
63. T. Storm, G. Thamsborg, T. Steiniche, H.K. Genant, and O.H. Sorensen Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis N. Engl. J. Med. 322 1990 1265 1271
64. U.A. Liberman, S.R. Weiss, J. Bröll, H.W. Minne, H. Quan, N.H. Bell, J. Rodriguez-Portales, R.W. Downs, J. Dequeker, M. Favus, E. Seeman, R.R. Recker, T. Capizzi, A.C. Santora, A. Lombardi, R.V. Shah, L.J. Hirsch, and D.B. Karpf Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis N. Engl. J. Med. 333 1995 1437 1444
65. D.M. Black, P.D. Delmas, R. Eastell, I.R. Reid, S. Boonen, J.A. Cauley, F. Cosman, P.t. Lakatos, P.C. Leung, Z. Man, C. Mautalen, P. Mesenbrink, H. Hu, J. Caminis, K. Tong, T. Rosario-Jansen, J. Krasnow, T.F. Hue, D. Sellmeyer, E.F. Eriksen, and S.R. Cummings Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N. Engl. J. Med. 356 2007 1809 1822
66. C.H. Chesnut, A. Skag, C. Christiansen, R. Recker, J.A. Stakkestad, A. Hoiseth, D. Felsenberg, H. Huss, J. Gilbride, R.C. Schimmer, and P.D. Delmas Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J. Bone Miner. Res. 19 2004 1241 1249
67. S.T. Harris, N.B. Watts, H.K. Genant, C.D. McKeever, T. Hangartner, M. Keller, C.H. Chesnut, J. Brown, E.F. Eriksen, M.S. Hoseyni, D.W. Axelrod, and P.D. Miller Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis JAMA 282 1999 1344 1352
68. I.R. Reid, J.P. Brown, P. Burckhardt, Z. Horowitz, P. Richardson, U. Trechsel, A. Widmer, J.-P. Devogelaer, J.-M. Kaufman, P. Jaeger, J.-J. Body, and P.J. Meunier Intravenous zoledronic acid in postmenopausal women with low bone mineral density N. Engl. J. Med. 346 2002 653 661
69. S. Silverman, N. Watts, P. Delmas, J. Lange, and R. Lindsay Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study Osteoporos. Int. 18 2007 25 34
70. M.K. Beard Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference Curr. Med. Res. Opin. 28 2012 141 147
71. R. Rizzoli Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM 104 2011 281 300
72. R.S. Weinstein Glucocorticoid-induced bone disease N. Engl. J. Med. 365 2011 62 70
73. R. Coleman The use of bisphosphonates in cancer treatment Ann. N. Y. Acad. Sci. 1218 2011 3 14
74. A.F. Stewart Hypercalcemia associated with cancer N. Engl. J. Med. 352 2005 373 379
75. M. Aapro, P.A. Abrahamsson, J.J. Body, R.E. Coleman, R. Colomer, L. Costa, L. Crinò, L. Dirix, M. Gnant, J. Gralow, P. Hadji, G.N. Hortobagyi, W. Jonat, A. Lipton, A. Monnier, A.H.G. Paterson, R. Rizzoli, F. Saad, and B. Thürlimann Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann. Oncol. 19 2008 420 432
76. M.J. Falk, S. Heeger, K.A. Lynch, K.R. DeCaro, D. Bohach, K.S. Gibson, and M.L. Warman Intravenous bisphosphonate therapy in children with osteogenesis imperfecta Pediatrics 111 2003 573 578
77. N.J. Shaw Management of osteoporosis in children Eur. J. Endocrinol. 159 2008 S33 S39
78. L.A. DiMeglio, and M. Peacock Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta J. Bone Miner. Res. 21 2006 132 140
79. K.J. August, A. Dalton, H.M. Katzenstein, B. George, T.A. Olson, K. Wasilewski-Masker, and L.B. Rapkin The use of zoledronic acid in pediatric cancer patients Pediatr. Blood Cancer 56 2011 610 614
80. M. Verdrengh, H. Carlsten, C. Ohlsson, and A. Tarkowski Addition of bisphosphonate to antibiotic and anti-inflammatory treatment reduces bone resorption in experimental Staphylococcus aureus-induced arthritis J. Orthop. Res. 25 2007 304 310
81. S.A. Lujan, L.M. Guogas, H. Ragonese, S.W. Matson, and M.R. Redinbo Disrupting antibiotic resistance propagation by inhibiting the conjugative DNA relaxase Proc. Natl. Acad. Sci. U.S.A. 104 2007 12282 12287
82. S. Girard, F. Paqué, M. Badertscher, B. Sener, and M. Zehnder Assessment of a gel-type chelating preparation containing 1-hydroxyethylidene-1, 1-bisphosphonate Int. Endod. J. 38 2005 810 816
83. R. Rizzoli, N. Burlet, D. Cahall, P.D. Delmas, E.F. Eriksen, D. Felsenberg, J. Grbic, M. Jontell, R. Landesberg, A. Laslop, M. Wollenhaupt, S. Papapoulos, O. Sezer, M. Sprafka, and J.-Y. Reginster Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis Bone 42 2008 841 847
84. S. Khosla, D. Burr, J. Cauley, D.W. Dempster, P.R. Ebeling, D. Felsenberg, R.F. Gagel, V. Gilsanz, T. Guise, S. Koka, L.K. McCauley, J. McGowan, M.D. McKee, S. Mohla, D.G. Pendrys, L.G. Raisz, S.L. Ruggiero, D.M. Shafer, L. Shum, S.L. Silverman, C.H. Van Poznak, N. Watts, S.-B. Woo, and E. Shane Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J. Bone Miner. Res. 22 2007 1479 1491
85. J. Schilcher, K. Michaëlsson, and P. Aspenberg Bisphosphonate use and atypical fractures of the femoral shaft N. Engl. J. Med. 364 2011 1728 1737
86. D.M. Black, M.P. Kelly, H.K. Genant, L. Palermo, R. Eastell, C. Bucci-Rechtweg, J. Cauley, P.C. Leung, S. Boonen, A. Santora, A. de Papp, and D.C. Bauer Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur N. Engl. J. Med. 362 2010 1761 1771
87. T. Tanvetyanon, and P.J. Stiff Management of the adverse effects associated with intravenous bisphosphonates Ann. Oncol. 17 2006 897 907
88. M. Pazianas, and B. Abrahamsen Safety of bisphosphonates Bone 49 2011 103 110
89. B. Abrahamsen Adverse effects of bisphosphonates Calcif. Tissue Int. 86 2010 421 435
90. D.E. Jensen, J. McGill, and J. Batch Nephrocalcinosis: a potential complication of bisphosphonate therapy in children J. Paediatr. Child Health 47 2011 929 930
91. X. Boulenc, E. Marti, H. Joyeux, C. Roques, Y. Berger, and G. Fabre Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model Biochem. Pharmacol. 46 1993 1591 1600
92. B.J. Gertz, S.D. Holland, W.F. Kline, B.K. Matuszewski, and A.G. Porras Clinical pharmacology of alendronate sodium Osteoporos. Int. 3 1993 13 16
93. M. Janner, R. Mühlbauer, and H. Fleisch Sodium EDTA enhances intestinal absorption of two bisphosphonates Calcif. Tissue Int. 49 1991 280 283
94. A. Ezra, A. Hoffman, E. Breuer, I.S. Alferiev, J. Mönkkönen, N. El Hanany-Rozen, G. Weiss, D. Stepensky, I. Gati, H. Cohen, S. Törmälehto, G.L. Amidon, and G. Golomb A peptide prodrug approach for improving bisphosphonate oral absorption J. Med. Chem. 43 2000 3641 3652
95. V. Dissette, P. Bozzi, C.A. Bignozzi, A. Dalpiaz, L. Ferraro, S. Beggiato, E. Leo, E. Vighi, and L. Pasti Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates Eur. J. Pharm. Sci. 41 2010 328 336
96. J.-S. Baek, H.-H. Kwon, J.-S. Hwang, H.-C. Sung, J.-M. Lee, S.-C. Shin, Y.R. Kim, and C.-W. Cho Alendronate-loaded microparticles for improvement of intestinal cellular absorption J. Drug Target. 19 2011 37 48
97. J. Smith, E. Wood, and M. Dornish Effect of chitosan on epithelial cell tight junctions Pharm. Res. 21 2004 43 49
98. H.K. Han, H.J. Shin, and D.H. Ha Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system Eur. J. Pharm. Sci. 46 2012 500 507
99. J. Meng, and L. Hu Positively-charged microemulsion for improving the oral bioavailability of alendronate: in-vitro and in-vivo assessment J. Pharm. Pharmacol. 63 2011 400 408
100. T.W. Leonard, J. Lynch, M.J. McKenna, and D.J. Brayden Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET™ Expert Opin. Drug Deliv. 3 2006 685 692
101. B. Aungst Absorption enhancers: applications and advances AAPS J. 14 2012 10 18
102. K. Whitehead, and S. Mitragotri Mechanistic analysis of chemical permeation enhancers for oral drug delivery Pharm. Res. 25 2008 1412 1419
103. H. Katsumi, S. Liu, Y. Tanaka, K. Hitomi, R. Hayashi, Y. Hirai, K. Kusamori, Y.S. Quan, F. Kamiyama, T. Sakane, and A. Yamamoto Development of a novel self-dissolving microneedle array of alendronate, a nitrogen-containing bisphosphonate: evaluation of transdermal absorption, safety, and pharmacological effects after application in rats J. Pharm. Sci. 101 2012 3230 3238
104. S.C. Sutton, K. Engle, and J.A. Fix Intranasal delivery of the bisphosphonate alendronate in the rat and dog Pharm. Res. 10 1993 924 926
105. L. Cruz, E. Fattal, L. Tasso, G.C. Freitas, A.B. Carregaro, S.S. Guterres, A.R. Pohlmann, and N. Tsapis Formulation and in vivo evaluation of sodium alendronate spray-dried microparticles intended for lung delivery J. Control. Release 152 2011 370 375
106. S. Samdancioglu, S. Calis, M. Sumnu, and A. Atilla Hincal Formulation and in vitro evaluation of bisphosphonate loaded microspheres for implantation in osteolysis Drug Dev. Ind. Pharm. 32 2006 473 481
107. P. Perugini, I. Genta, B. Conti, T. Modena, and F. Pavanetto Long-term release of clodronate from biodegradable microspheres AAPS PharmSciTech 2 2001 6 14
108. Y. Zou, J.L. Brooks, V. Talwalkar, T.A. Milbrandt, and D.A. Puleo Development of an injectable two-phase drug delivery system for sequential release of antiresorptive and osteogenic drugs J. Biomed. Mater. Res. B 100B 2011 155 162
109. S. Josse, C. Faucheux, A. Soueidan, G. Grimandi, D. Massiot, B. Alonso, P. Janvier, S. Laïb, O. Gauthier, G. Daculsi, J. Guicheux, B. Bujoli, and J.M. Bouler Chemically modified calcium phosphates as novel materials for bisphosphonate delivery Adv. Mater. 16 2004 1423 1427
110. E. Verron, O. Gauthier, P. Janvier, P. Pilet, J. Lesoeur, B. Bujoli, J. Guicheux, and J.-M. Bouler In vivo bone augmentation in an osteoporotic environment using bisphosphonate-loaded calcium deficient apatite Biomaterials 31 2010 7776 7784
111. F. Fanord, K. Fairbairn, H. Kim, A. Garces, V. Bhethanabotla, and V.K. Gupta Bisphosphonate-modified gold nanoparticles: a useful vehicle to study the treatment of osteonecrosis of the femoral head Nanotechnology 22 2011 1 11
112. J. Aya-ay, S. Athavale, S. Morgan-Bagley, H. Bian, F. Bauss, and H.K.W. Kim Retention, distribution, and effects of intraosseously administered ibandronate in the infarcted femoral head J. Bone Miner. Res. 22 2007 93 100
113. R.D. Ross, and R.K. Roeder Binding affinity of surface functionalized gold nanoparticles to hydroxyapatite J. Biomed. Mater. Res. A 99A 2011 58 66
114. A.M. Miller, A.R. McPhaden, R.M. Wadsworth, and C.L. Wainwright Inhibition by leukocyte depletion of neointima formation after balloon angioplasty in a rabbit model of restenosis Cardiovasc. Res. 49 2001 838 850
115. H. Epstein-Barash, D. Gutman, E. Markovsky, G. Mishan-Eisenberg, N. Koroukhov, J. Szebeni, and G. Golomb Physicochemical parameters affecting liposomal bisphosphonates bioactivity for restenosis therapy: internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death J. Control. Release 146 2010 182 195
116. E. Cohen-Sela, O. Rosenzweig, J. Gao, H. Epstein, I. Gati, R. Reich, H.D. Danenberg, and G. Golomb Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis J. Control. Release 113 2006 23 30
117. D. Gutman, and G. Golomb Liposomal alendronate for the treatment of restenosis J. Control. Release 161 2012 619 627
118. E. Haber, H.D. Danenberg, N. Koroukhov, R. Ron-El, G. Golomb, and M. Schachter Peritoneal macrophage depletion by liposomal bisphosphonate attenuates endometriosis in the rat model Hum. Reprod. 24 2009 398 407
119. P.J. Richards, B.D. Williams, and A.S. Williams Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate Rheumatology (Oxford) 40 2001 978 987
120. E. Haber, E. Afergan, H. Epstein, D. Gutman, N. Koroukhov, M. Ben-David, M. Schachter, and G. Golomb Route of administration-dependent anti-inflammatory effect of liposomal alendronate J. Control. Release 148 2010 226 233
121. M.A. Quadir, M.R. Radowski, F. Kratz, K. Licha, P. Hauff, and R. Haag Dendritic multishell architectures for drug and dye transport J. Control. Release 132 2008 289 294
122. S.M. Zeisberger, B. Odermatt, C. Marty, A.H.M. Zehnder-Fjallman, K. Ballmer-Hofer, and R.A. Schwendener Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach Br. J. Cancer 95 2006 272 281
123. Y. Meng, M.A. Beckett, H. Liang, H.J. Mauceri, N. van Rooijen, K.S. Cohen, and R.R. Weichselbaum Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy Cancer Res. 70 2010 1534 1543
124. M. Marra, G. Salzano, C. Leonetti, P. Tassone, M. Scarsella, S. Zappavigna, T. Calimeri, R. Franco, G. Liguori, G. Cigliana, R. Ascani, M.I. La Rotonda, A. Abbruzzese, P. Tagliaferri, M. Caraglia, and G. De Rosa Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes Nanomedicine 7 2011 955 964
125. G. Salzano, M. Marra, M. Porru, S. Zappavigna, A. Abbruzzese, M.I. La Rotonda, C. Leonetti, M. Caraglia, and G. De Rosa Self-assembly nanoparticles for the delivery of bisphosphonates into tumors Int. J. Pharm. 403 2011 292 297
126. M. Marra, G. Salzano, C. Leonetti, M. Porru, R. Franco, S. Zappavigna, G. Liguori, G. Botti, P. Chieffi, M. Lamberti, G. Vitale, A. Abbruzzese, M.I. La Rotonda, G. De Rosa, and M. Caraglia New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study Biotechnol. Adv. 30 2012 302 309
127. H. Shmeeda, Y. Amitay, J. Gorin, D. Tzemach, L. Mak, J. Ogorka, S. Kumar, J.A. Zhang, and A. Gabizon Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells J. Control. Release 146 2010 76 83
128. F. Benyettou, Y. Lalatonne, I. Chebbi, M.D. Benedetto, J.-M. Serfaty, M. Lecouvey, and L. Motte A multimodal magnetic resonance imaging nanoplatform for cancer theranostics Phys. Chem. Chem. Phys. 13 2011 10020 10027
129. G.S. Ashcroft, M.A. Horan, S.E. Herrick, R.W. Tarnuzzer, G.S. Schultz, and M.W.J. Ferguson Age-related differences in the temporal and spatial regulation of matrix metalloproteinases (MMPs) in normal skin and acute cutaneous wounds of healthy humans Cell Tissue Res. 290 1997 581 591
130. E.A. Rayment, T.R. Dargaville, G.K. Shooter, G.A. George, and Z. Upton Attenuation of protease activity in chronic wound fluid with bisphosphonate-functionalised hydrogels Biomaterials 29 2008 1785 1795
131. J. Karrholm, B. Borssen, G. Lowenhielm, and F. Snorrason Does early micromotion of femoral stem prostheses matter? 4-7-Year stereoradiographic follow-up of 84 cemented prostheses J. Bone Joint Surg. Br. 76-B 1994 912 917
132. H.-J. Moon, Y.-P. Yun, C.-W. Han, M.S. Kim, S.E. Kim, M.S. Bae, G.-T. Kim, Y.-S. Choi, E.-H. Hwang, J.W. Lee, J.-M. Lee, C.-H. Lee, D.-S. Kim, and I.K. Kwon Effect of heparin and alendronate coating on titanium surfaces on inhibition of osteoclast and enhancement of osteoblast function Biochem. Biophys. Res. Commun. 413 2011 194 200
133. F. Agholme, T. Andersson, P. Tengvall, and P. Aspenberg Local bisphosphonate release versus hydroxyapatite coating for stainless steel screw fixation in rat tibiae J. Mater. Sci. Mater. Med. 23 2012 743 752
134. Y. Gao, S. Zou, X. Liu, C. Bao, and J. Hu The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats Biomaterials 30 2009 1790 1796
135. B. Peter, D.P. Pioletti, S. Laïb, B. Bujoli, P. Pilet, P. Janvier, J. Guicheux, P.Y. Zambelli, J.M. Bouler, and O. Gauthier Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration Bone 36 2005 52 60
136. A. Ganguli, C. Steward, S.L. Butler, G.J. Philips, S.T. Meikle, A.W. Lloyd, and M.H. Grant Bacterial adhesion to bisphosphonate coated hydroxyapatite J. Mater. Sci. Mater. Med. 16 2005 283 287
137. J. Forsgren, U. Brohede, M. Strømme, and H. Engqvist Co-loading of bisphosphonates and antibiotics to a biomimetic hydroxyapatite coating Biotechnol. Lett. 33 2011 1265 1268
138. I. Alferiev, N. Vyavahare, C. Song, J. Connolly, J. Travis Hinson, Z. Lu, S. Tallapragada, R. Bianco, and R. Levy Bisphosphonate derivatized polyurethanes resist calcification Biomaterials 22 2001 2683 2693
139. R. Torres Martin de Rosales, R. Tavaré, R.L. Paul, M. Jauregui-Osoro, A. Protti, A. Glaria, G. Varma, I. Szanda, and P.J. Blower Synthesis of 64CuII-bis(dithiocarbamatebisphosphonate) and its conjugation with superparamagnetic iron oxide nanoparticles: in vivo evaluation as dual-modality PET-MRI agent Angew. Chem. Int. Ed. 50 2011 5509 5513
140. E.V. Giger, J. Puigmartí-Luis, R. Schlatter, B. Castagner, P.S. Dittrich, and J.-C. Leroux Gene delivery with bisphosphonate-stabilized calcium phosphate nanoparticles J. Control. Release 150 2011 87 93
141. Y. Lalatonne, C. Paris, J.M. Serfaty, P. Weinmann, M. Lecouvey, and L. Motte Bis-phosphonates-ultra small superparamagnetic iron oxide nanoparticles: a platform towards diagnosis and therapy Chem. Commun. 2008 2553 2555
142. L. Motte, F. Benyettou, C. de Beaucorps, M. Lecouvey, I. Milesovic, and Y. Lalatonne Multimodal superparamagnetic nanoplatform for clinical applications: immunoassays, imaging & therapy Faraday Discuss. 149 2011 211 225
143. D. Wang, S. Miller, M. Sima, P. Kopečková, and J. Kopeček Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems Bioconjug. Chem. 14 2003 853 859
144. K. Miller, R. Erez, E. Segal, D. Shabat, and R. Satchi-Fainaro Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate Angew. Chem. Int. Ed. 48 2009 2949 2954
145. H. Uludag, and J. Yang Targeting systemically administered proteins to bone by bisphosphonate conjugation Biotechnol. Prog. 18 2002 604 611
146. S.A. Gittens, G. Bansal, C. Kucharski, M. Borden, and H. Uludag Imparting mineral affinity to fetuin by bisphosphonate conjugation: a comparison of three bisphosphonate conjugation schemes Mol. Pharm. 2 2005 392 406
147. M.B. Murphy, J.D. Hartgerink, A. Goepferich, and A.G. Mikos Synthesis and in vitro hydroxyapatite binding of peptides conjugated to calcium-binding moieties Biomacromolecules 8 2007 2237 2243
148. K.H. Bhandari, M. Newa, J. Chapman, and M.R. Doschak Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats J. Control. Release 158 2012 44 52
149. G. Wang, N.Z. Mostafa, V. Incani, C. Kucharski, and H. Uludag Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases J. Biomed. Mater. Res. A 100A 2012 684 693
150. J. Fujisaki, Y. Tokunaga, T. Takahashi, F. Shimojo, S. Kimura, and T. Hata Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. IV
151. S.D. Bain, M.C. Bailey, D.L. Celino, M.M. Lantry, and M.W. Edwards High-dose estrogen inhibits bone resorption and stimulates bone formation in the ovariectomized mouse J. Bone Miner. Res. 8 1993 435 442
152. G.A. Colditz, S.E. Hankinson, D.J. Hunter, W.C. Willett, J.E. Manson, M.J. Stampfer, C. Hennekens, B. Rosner, and F.E. Speizer The use of estrogens and progestins and the risk of breast cancer in postmenopausal women N. Engl. J. Med. 332 1995 1589 1593
153. F. Bauss, A. Esswein, K. Reiff, G. Sponer, and B. Müller-Beckmann Effect of 17β-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17β-estradiol serum kinetics and bone mass in rats Calcif. Tissue Int. 59 1996 168 173
154. S. Arns, R. Gibe, A. Moreau, M. Monzur Morshed, and R.N. Young Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis Bioorg. Med. Chem. 20 2012 2131 2140
155. C. Clementi, K. Miller, A. Mero, R. Satchi-Fainaro, and G. Pasut Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms Mol. Pharm. 8 2011 1063 1072
156. F.M. Paes, and A.N. Serafini Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain Semin. Nucl. Med. 40 2010 89 104
157. L. Bodei, M. Lam, C. Chiesa, G. Flux, B. Brans, A. Chiti, and F. Giammarile EANM procedure guideline for treatment of refractory metastatic bone pain Eur. J. Nucl. Med. Mol. Imaging 35 2008 1934 1940
158. J.M.H. de Klerk, A. van Dijk, A.D. van het Schip, B.A. Zonnenberg, and P.P. van Rijk Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases J. Nucl. Med. 33 1992 646 651
159. K. Ogawa, T. Mukai, D. Asano, H. Kawashima, S. Kinuya, K. Shiba, K. Hashimoto, H. Mori, and H. Saji Therapeutic effects of a 186Re-complex- conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model J. Nucl. Med. 48 2007 122 127
160. 188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases Bioconjug. Chem. 21 2010 811 815
161. W. Liu, A. Hajibeigi, M. Lin, C.L. Rostollan, Z. Kovacs, O.K. Öz, and X. Sun An osteoclast-targeting agent for imaging and therapy of bone metastasis Bioorg. Med. Chem. Lett. 18 2008 4789 4793
162. M.M. Reinholz, S.P. Zinnen, A.C. Dueck, D. Dingli, G.G. Reinholz, L.A. Jonart, K.A. Kitzmann, A.K. Bruzek, V. Negron, A.K. Abdalla, B.K. Arendt, A.J. Croatt, L. Sanchez-Perez, D.P. Sebesta, H. Lönnberg, T. Yoneda, K.A. Nath, D.F. Jelinek, S.J. Russell, J.N. Ingle, T.C. Spelsberg, H.B.F. Dixon, A. Karpeisky, and W.L. Lingle A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites Bone 47 2010 12 22
163. K. Hochdorffer, K. Abu Ajaj, C. Schafer-Obodozie, and F. Kratz Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix J. Med. Chem. 55 2012 7502 7515
164. A.A. El-Mabhouh, and J.R. Mercer Re-188-labelled gemcitabine/ bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases Eur. J. Nucl. Med. Mol. Imaging 35 2008 1240 1248
165. P. Herczegh, T.B. Buxton, J.C. McPherson III, Á. Kovács-Kulyassa, P.D. Brewer, F. Sztaricskai, G.G. Stroebel, K.M. Plowman, D. Farcasiu, and J.F. Hartmann Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials J. Med. Chem. 45 2002 2338 2341
166. J.C. McPherson III, R. Runner, T.B. Buxton, J.F. Hartmann, D. Farcasiu, I. Bereczki, E. Roth, S. Tollas, E. Ostorházi, F. Rozgonyi, and P. Herczegh Synthesis of osteotropic hydroxybisphosphonate derivatives of fluoroquinolone antibacterials Eur. J. Med. Chem. 47 2012 615 618
167. T.B. Buxton, D.S. Walsh, S.B. Harvey, J.C. McPherson III, J.F. Hartmann, and K.M. Plowman Bisphosphonate-ciprofloxacin bound to Skelite™ is a prototype for enhancing experimental local antibiotic delivery to injured bone Br. J. Surg. 91 2004 1192 1196
168. T.J. Houghton, K.S.E. Tanaka, T. Kang, E. Dietrich, Y. Lafontaine, D. Delorme, S.S. Ferreira, F. Viens, F.F. Arhin, I. Sarmiento, D. Lehoux, I. Fadhil, K. Laquerre, J. Liu, V.r. Ostiguy, H. Poirier, G. Moeck, T.R. Parr, and A.R. Far Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis J. Med. Chem. 51 2008 6955 6969
169. J.E.I. Wright, S.A. Gittens, G. Bansal, P.I. Kitov, D. Sindrey, C. Kucharski, and H. Uludag A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages Biomaterials 27 2006 769 784
170. S. Gittens, P. Kitov, J. Matyas, R. Löbenberg, and H. Uludaǧ Impact of tether length on bone mineral affinity of protein-bisphosphonate conjugates Pharm. Res. 21 2004 608 616
171. R.S. Ehrick, M. Capaccio, D.A. Puleo, and L.G. Bachas Ligand-modified aminobisphosphonate for linking proteins to hydroxyapatite and bone surface Bioconjug. Chem. 19 2007 315 321
172. M. Zaidi, M. Pazianas, V. Shankar, B. Bax, C. Bax, P. Bevis, C. Stevens, C. Huang, D. Blake, and B. Moonga Osteoclast function and its control Exp. Physiol. 78 1993 721 739
173. K.H. Bhandari, M. Newa, H. Uludag, and M.R. Doschak Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin Int. J. Pharm. 394 2010 26 34
174. M. Guan, W. Yao, R. Liu, K.S. Lam, J. Nolta, J. Jia, B. Panganiban, L. Meng, P. Zhou, M. Shahnazari, R.O. Ritchie, and N.E. Lane Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass Nat. Med. 18 2012 456 462
175. H. Pan, M. Sima, P. Kopečková, K. Wu, S. Gao, J. Liu, D. Wang, S.C. Miller, and J.i. Kopeček Biodistribution and pharmacokinetic studies of bone-targeting N-(2-hydroxypropyl)methacrylamide copolymer- alendronate conjugates Mol. Pharm. 5 2008 548 558
176. K. Miller, A. Eldar-Boock, D. Polyak, E. Segal, L. Benayoun, Y. Shaked, and R. Satchi-Fainaro Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model Mol. Pharm. 8 2011 1052 1062
177. E. Segal, H. Pan, L. Benayoun, P. Kopečková, Y. Shaked, J. Kopeček, and R. Satchi-Fainaro Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances Biomaterials 32 2011 4450 4463
178. R. Pignatello, E. Cenni, D. Micieli, C. Fotia, M. Salerno, D. Granchi, S. Avnet, M.G. Sarpietro, F. Castelli, and N. Baldini A novel biomaterial for osteotropic drug nanocarriers: synthesis and biocompatibility evaluation of a PLGA-ALE conjugate Nanomedicine 4 2009 161 175
179. E. Cenni, D. Granchi, S. Avnet, C. Fotia, M. Salerno, D. Micieli, M.G. Sarpietro, R. Pignatello, F. Castelli, and N. Baldini Biocompatibility of poly(d, l-lactide-co-glycolide) nanoparticles conjugated with alendronate Biomaterials 29 2008 1400 1411
180. S.-W. Choi, and J.-H. Kim Design of surface-modified poly(d, l-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone J. Control. Release 122 2007 24 30
181. K.R. Chaudhari, A. Kumar, V.K.M. Khandelwal, M. Ukawala, A.S. Manjappa, A.K. Mishra, J. Monkkonen, and R.S.R. Murthy Bone metastasis targeting: a novel approach to reach bone using zoledronate anchored PLGA nanoparticle as carrier system loaded with docetaxel J. Control. Release 158 2012 470 478
182. S.I. Thamake, S.L. Raut, Z. Gryczynski, A.P. Ranjan, and J.K. Vishwanatha Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer Biomaterials 33 2012 7164 7173
183. N. Bertrand, and J.-C. Leroux The journey of a drug-carrier in the body: an anatomo-physiological perspective J. Control. Release 161 2012 152 163
184. K.R. Chaudhari, A. Kumar, V.K.M. Khandelwal, A.K. Mishra, J. Monkkonen, and R.S.R. Murthy Targeting efficiency and biodistribution of zoledronate conjugated docetaxel loaded pegylated PBCA nanoparticles for bone metastasis Adv. Funct. Mater. 22 2012 4101 4114
185. V. Hengst, C. Oussoren, T. Kissel, and G. Storm Bone targeting potential of bisphosphonate-targeted liposomes: preparation, characterization and hydroxyapatite binding in vitro Int. J. Pharm. 331 2007 224 227
186. T. Anada, Y. Takeda, Y. Honda, K. Sakurai, and O. Suzuki Synthesis of calcium phosphate-binding liposome for drug delivery Bioorg. Med. Chem. Lett. 19 2009 4148 4150
187. A. Hernandez-Santana, A. Yavorskyy, A. Olinyole, G.M. McCarthy, and G.P. McMahon Isolation of calcium phosphate crystals from complex biological fluids using bisphosphonate-modified superparamagnetic beads Chem. Commun. 2008 2686 2688
188. L. Wang, Z. Yang, J. Gao, K. Xu, H. Gu, B. Zhang, X. Zhang, and B. Xu A biocompatible method of decorporation: bisphosphonate-modified magnetite nanoparticles to remove uranyl ions from blood J. Am. Chem. Soc. 128 2006 13358 13359
189. B. Denizot, F. Hindré, and D. Portet Bisphosphonic compounds for preventing or limiting fixing of macromolecules, microorganisms and biofilm on solid, in particular metal or mineral surfaces, US2008/0220037A1 2008
190. P.J. Bekker, D.L. Holloway, A.S. Rasmussen, R. Murphy, S.W. Martin, P.T. Leese, G.B. Holmes, C.R. Dunstan, and A.M. DePaoli A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J. Bone Miner. Res. 19 2004 1059 1066
191. D.L. Lacey, W.J. Boyle, W.S. Simonet, P.J. Kostenuik, W.C. Dougall, J.K. Sullivan, J.S. Martin, and R. Dansey Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab Nat. Rev. Drug Discov. 11 2012 401 419